Janssen Reports Submission of MAA to EMA for its Investigational Ebola Vaccine Regimen to Prevent Ebola Virus Disease

 Janssen Reports Submission of MAA to EMA for its Investigational Ebola Vaccine Regimen to Prevent Ebola Virus Disease

Janssens Reports Results of Tremfya (guselkumab) in Two P-III DISCOVER Studies for Psoriatic Arthritis

Shots:

  • Janssen has submitted MAA to EMA for an investigational Ebola vaccine regimen in two doses Ad26.ZEBOV, MVA-BN-Filo for the prevention of Ebola Virus Disease (EVD) caused by Zaire ebolavirus species. In Sept’2019, EMA’s CHMP has granted an accelerated
  • The MAA is based on multiple preclinical, P-I, II & III studies evaluating the safety and immunogenicity of the vaccine regimen in adults and children in 6,500+ volunteers across the US, EU and Africa
  • The vaccine regimen includes Ad26.ZEBOV as the first dose, based on Janssen’s AdVac technology and MVA-BN-Filo as the second dose, based on Bavarian Nordic’s MVA-BN technology and is administered ~8wks. later. Additionally, Janssen is working with WHO to register Ebola vaccine regimen in African countries

Click here to­ read full press release/ article | Ref: Janssen  | Image: The Boston Globe

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post